论文部分内容阅读
目的 探讨复方中药“抗纤Ⅰ号”方在慢性肝炎患者中抗肝纤维化的作用。方法 选择 70只Wistar大鼠 ,取10只作为正常对照组 ,余 60只给予 40 %四氯化碳橄榄油混合液建立实验性大鼠肝纤维化模型 ,将大鼠均分为 4组 :(1)肝纤维化模型组仅灌生理盐水 ;(2 )中药组灌服“抗纤Ⅰ号”方药 ;(3 )秋水仙碱组灌服秋水仙碱 ;(4 )干扰素组肌肉注射γ 干扰素。均治疗 8周后取鼠肝右叶作病理检查。 63例慢性肝炎肝纤维化患者分成 3组 :(1)中药组 3 4例接受“抗纤Ⅰ号”方治疗 ;(2 )对照组 14例给予传统护肝治疗 ;(3 )干扰素组 15例给予重组γ 干扰素治疗。结果 从动物实验模型上发现 ,中药组灌胃治疗后肝纤维化评分值与秋水仙碱组相比无显著性差异 (P >0 .0 5 ) ,病理检查示肝组织炎症坏死明显吸收好转。临床观察显示 ,中药组与对照组比较肝纤维化患者丙氨酸氨基转移酶 (ALT)、总胆红素 (TBil)和Ⅳ型胶原 (PⅣ)水平降低更明显 (P <0 .0 5 ) ;与干扰素相比 ,中药同样能改善患者的乏力和腹胀症状 ,并一定程度地缩小门、脾静脉内径和脾脏厚径(P >0 .0 5 ) ,未见明显不良反应。结论 “抗纤Ⅰ号”方在肝纤维化模型上具有与秋水仙碱相当的抗炎和抗纤维化作用 ,临床上具有护肝、降酶、退黄和软肝功效 ,疗效优于传统的常规治
Objective To investigate the anti-hepatic fibrosis effect of compound Chinese medicine “Kangxian I” in chronic hepatitis. Methods Seventy Wistar rats were selected and 10 rats were selected as the normal control group. The remaining 60 rats were given 40% carbon tetrachloride olive oil mixture to establish experimental rat liver fibrosis model. The rats were divided into 4 groups: 1) the model group of liver fibrosis was only given saline; (2) the traditional Chinese medicine group was given “Kangxian No.1” prescription; (3) the colchicine group was given colchicine; (4) Prime After 8 weeks of treatment, the right lobe of rat was taken for pathological examination. Sixty-three patients with chronic hepatitis with liver fibrosis were divided into three groups: (1) 34 patients in the traditional Chinese medicine group were treated with “Anti-fibrosis I”; (2) 14 patients in the control group were treated with traditional liver protection; (3) Interferon group 15 Cases given recombinant interferon gamma treatment. Results From the animal experimental model, we found that there is no significant difference in the score of liver fibrosis between the TCM group and the colchicine group (P> 0.05). Pathological examination showed that the liver tissue inflammation and necrosis improved obviously. Clinical observation showed that the levels of ALT, TBil and PⅣ in patients with liver fibrosis were significantly lower than those in the control group (P <0.05) Compared with interferon, traditional Chinese medicine can also improve the patient’s fatigue and abdominal distension symptoms, and to some extent reduce the diameter of spleen and portal vein, and the diameter of spleen (P> 0.05), no obvious adverse reactions. Conclusion “Anti-fibrosis Ⅰ” has the anti-inflammatory and anti-fibrosis effects comparable to colchicine in liver fibrosis model. It has the functions of protecting liver, reducing enzyme, excreting yellow and soft liver and has better curative effect than traditional Routine treatment